282 related articles for article (PubMed ID: 35767258)
41. Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma.
Jin YJ; Shim JH; Lee HC; Yoo DJ; Kim KM; Lim YS; Suh DJ
J Gastroenterol Hepatol; 2011 Sep; 26(9):1380-8. PubMed ID: 21884247
[TBL] [Abstract][Full Text] [Related]
42. Five-year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment-naïve patients with chronic hepatitis B-related compensated cirrhosis in Taiwan.
Hu TH; Yueh-Hsia Chiu S; Tseng PL; Chen CH; Lu SN; Wang JH; Hung CH; Kee KM; Lin MT; Chang KC; Lin MC; Chien RN
Aliment Pharmacol Ther; 2020 Dec; 52(11-12):1695-1706. PubMed ID: 33111400
[TBL] [Abstract][Full Text] [Related]
43. Temporal trend and risk determinants of hepatocellular carcinoma in chronic hepatitis B patients on entecavir or tenofovir.
Hsu YC; Ho HJ; Lee TY; Huang YT; Wu MS; Lin JT; Wu CY; El-Serag HB
J Viral Hepat; 2018 May; 25(5):543-551. PubMed ID: 29193536
[TBL] [Abstract][Full Text] [Related]
44. Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir.
Chang JW; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Seo YS; Lee HA; Kim MN; Lee YR; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Park SY; Kim SU
J Viral Hepat; 2021 Jan; 28(1):95-104. PubMed ID: 33029863
[TBL] [Abstract][Full Text] [Related]
45. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B.
Hsu YC; Yip TC; Ho HJ; Wong VW; Huang YT; El-Serag HB; Lee TY; Wu MS; Lin JT; Wong GL; Wu CY
J Hepatol; 2018 Aug; 69(2):278-285. PubMed ID: 29551708
[TBL] [Abstract][Full Text] [Related]
46. Mortality, liver transplantation and hepatic complications in patients with treatment-naïve chronic hepatitis B treated with entecavir vs tenofovir.
Kim BG; Park NH; Lee SB; Lee H; Lee BU; Park JH; Jung SW; Jeong ID; Bang SJ; Shin JW
J Viral Hepat; 2018 Dec; 25(12):1565-1575. PubMed ID: 29998592
[TBL] [Abstract][Full Text] [Related]
47. Meta-analysis of the occurrence of hepatocellular carcinoma after the treatment of entecavir and tenofovir for chronic hepatitis B.
Tang K; Cheng H; Wang H; Guo Y
Medicine (Baltimore); 2023 Feb; 102(6):e32894. PubMed ID: 36820558
[TBL] [Abstract][Full Text] [Related]
48. Risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States.
Kim WR; Telep LE; Jump B; Lu M; Ramroth H; Flaherty J; Gaggar A; Chokkalingam AP; Gordon SC
Aliment Pharmacol Ther; 2022 Apr; 55(7):828-835. PubMed ID: 35137422
[TBL] [Abstract][Full Text] [Related]
49. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis.
Wang X; Liu X; Dang Z; Yu L; Jiang Y; Wang X; Yan Z
Gut Liver; 2020 Mar; 14(2):232-247. PubMed ID: 31158948
[TBL] [Abstract][Full Text] [Related]
50. Comparative efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: A systematic review and meta-analysis.
Chen MB; Wang H; Zheng QH; Zheng XW; Fan JN; Ding YL; Niu JL
PLoS One; 2019; 14(11):e0224773. PubMed ID: 31751366
[TBL] [Abstract][Full Text] [Related]
51. Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study.
Wu IT; Hu TH; Hung CH; Lu SN; Wang JH; Lee CM; Chen CH
Clin Microbiol Infect; 2017 Jul; 23(7):464-469. PubMed ID: 28189857
[TBL] [Abstract][Full Text] [Related]
52. Comparison of the Efficacy of Tenofovir Versus Tenofovir plus Entecavir in the Treatment of Chronic Hepatitis B in Patients With Poor Efficacy of Entecavir: A Systematic Review and Meta-analysis.
Chen J; Zhao SS; Liu XX; Huang ZB; Huang Y
Clin Ther; 2017 Sep; 39(9):1870-1880. PubMed ID: 28797777
[TBL] [Abstract][Full Text] [Related]
53. Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B.
Yip TC; Wong GL; Wong VW; Tse YK; Liang LY; Hui VW; Lee HW; Lui GC; Chan HL
J Hepatol; 2020 May; 72(5):847-854. PubMed ID: 31857194
[TBL] [Abstract][Full Text] [Related]
54. Tenofovir versus entecavir for tertiary prevention of hepatocellular carcinoma in chronic hepatitis B infection after curative therapy: A systematic review and meta-analysis.
Giri S; Agrawal D; Afzalpurkar S; Gopan A; Angadi S; Sundaram S
J Viral Hepat; 2023 Feb; 30(2):108-115. PubMed ID: 36321967
[TBL] [Abstract][Full Text] [Related]
55. Validation of the HCC-RESCUE score to predict hepatocellular carcinoma risk in Caucasian chronic hepatitis B patients under entecavir or tenofovir therapy.
Güzelbulut F; Gökçen P; Can G; Adalı G; Değirmenci Saltürk AG; Bahadır Ö; Özdil K; Doğanay HL
J Viral Hepat; 2021 May; 28(5):826-836. PubMed ID: 33586270
[TBL] [Abstract][Full Text] [Related]
56. Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma.
Lee SW; Choi J; Kim SU; Lim YS
Clin Mol Hepatol; 2021 Jul; 27(3):402-412. PubMed ID: 34157830
[TBL] [Abstract][Full Text] [Related]
57. Validation of PAGE-B model in Asian chronic hepatitis B patients receiving entecavir or tenofovir.
Kim MN; Hwang SG; Rim KS; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Kim SU
Liver Int; 2017 Dec; 37(12):1788-1795. PubMed ID: 28418595
[TBL] [Abstract][Full Text] [Related]
58. Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B.
Lee HW; Cho YY; Lee H; Lee JS; Kim SU; Park JY; Kim DY; Ahn SH; Kim BK; Park SY
J Viral Hepat; 2021 Nov; 28(11):1570-1578. PubMed ID: 34435412
[TBL] [Abstract][Full Text] [Related]
59. Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog.
Kirino S; Tamaki N; Kaneko S; Kurosaki M; Inada K; Yamashita K; Osawa L; Hayakawa Y; Sekiguchi S; Watakabe K; Okada M; Wang W; Shimizu T; Higuchi M; Takaura K; Maeyashiki C; Yasui Y; Nakanishi H; Tsuchiya K; Itakura J; Takahashi Y; Izumi N
J Gastroenterol Hepatol; 2020 Sep; 35(9):1595-1601. PubMed ID: 31975419
[TBL] [Abstract][Full Text] [Related]
60. The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma.
Lee JH; Kim BK; Park SY; Tak WY; Park JY; Kim DY; Ahn SH; Sinn DH; Kim SU
Eur J Intern Med; 2021 Jul; 89():48-55. PubMed ID: 33810942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]